However, antagonists like H-151 and C-176 are also being investigated in cancers associated with chronic inflammation, where reducing STING activity could help minimize tumor-promoting inflammation, especially in hepatocellular carcinoma and pancreatic cancer models (136, 137). Here, STING1 is linked to cancer.